Annual FCF
$41.95 M
+$655.28 M+106.84%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual free cash flow is currently $41.95 million, with the most recent change of +$655.28 million (+106.84%) on 31 December 2023. During the last 3 years, it has risen by +$760.01 million (+105.84%). ALNY annual FCF is now -77.78% below its all-time high of $188.73 million, reached on 31 December 2007.ALNY Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$39.52 M
-$76.63 M-65.98%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly free cash flow is currently $39.52 million, with the most recent change of -$76.63 million (-65.98%) on 30 September 2024. Over the past year, it has increased by +$84.62 million (+187.61%). ALNY quarterly FCF is now -88.46% below its all-time high of $342.32 million, reached on 30 September 2023.ALNY Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$16.06 M
-$302.81 M-94.96%
30 September 2024
Summary:
Alnylam Pharmaceuticals TTM free cash flow is currently $16.06 million, with the most recent change of -$302.81 million (-94.96%) on 30 September 2024. Over the past year, it has dropped by -$25.88 million (-61.70%). ALNY TTM FCF is now -94.96% below its all-time high of $318.87 million, reached on 30 June 2024.ALNY TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +187.6% | -61.7% |
| 3 y3 years | +105.8% | +123.0% | +102.2% |
| 5 y5 years | +110.0% | +116.8% | +103.8% |
ALNY Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +105.8% | -88.5% | +120.9% | -95.0% | +102.2% |
| 5 y | 5 years | at high | +105.8% | -88.5% | +114.9% | -95.0% | +101.8% |
| alltime | all time | -77.8% | +105.8% | -88.5% | +114.9% | -95.0% | +101.8% |
Alnylam Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $39.52 M(-66.0%) | $16.06 M(-95.0%) |
| June 2024 | - | $116.14 M(-222.9%) | $318.87 M(+149.5%) |
| Mar 2024 | - | -$94.49 M(+109.5%) | $127.82 M(+204.7%) |
| Dec 2023 | $41.95 M(-106.8%) | -$45.10 M(-113.2%) | $41.95 M(-163.0%) |
| Sept 2023 | - | $342.32 M(-557.0%) | -$66.56 M(-87.7%) |
| June 2023 | - | -$74.91 M(-58.5%) | -$540.68 M(-10.6%) |
| Mar 2023 | - | -$180.37 M(+17.4%) | -$604.65 M(-1.4%) |
| Dec 2022 | -$613.33 M(-14.6%) | -$153.61 M(+16.6%) | -$613.33 M(-2.9%) |
| Sept 2022 | - | -$131.79 M(-5.1%) | -$631.75 M(-4.3%) |
| June 2022 | - | -$138.87 M(-26.5%) | -$660.05 M(+0.9%) |
| Mar 2022 | - | -$189.05 M(+9.9%) | -$654.28 M(-8.9%) |
| Dec 2021 | -$718.07 M(+4.8%) | -$172.03 M(+7.5%) | -$718.07 M(+3.9%) |
| Sept 2021 | - | -$160.10 M(+20.3%) | -$690.85 M(+5.7%) |
| June 2021 | - | -$133.10 M(-47.4%) | -$653.50 M(-2.8%) |
| Mar 2021 | - | -$252.84 M(+74.6%) | -$672.38 M(-1.9%) |
| Dec 2020 | -$685.32 M(+63.7%) | -$144.81 M(+18.0%) | -$685.32 M(-11.6%) |
| Sept 2020 | - | -$122.74 M(-19.2%) | -$775.29 M(-11.0%) |
| June 2020 | - | -$151.99 M(-42.8%) | -$871.24 M(+92.8%) |
| Mar 2020 | - | -$265.78 M(+13.2%) | -$451.80 M(+7.9%) |
| Dec 2019 | -$418.58 M(-39.3%) | -$234.78 M(+7.4%) | -$418.58 M(+12.6%) |
| Sept 2019 | - | -$218.69 M(-181.8%) | -$371.77 M(+5.5%) |
| June 2019 | - | $267.45 M(-215.0%) | -$352.30 M(-52.7%) |
| Mar 2019 | - | -$232.56 M(+23.7%) | -$745.14 M(+8.1%) |
| Dec 2018 | -$689.50 M(+41.6%) | -$187.97 M(-5.6%) | -$689.50 M(+10.3%) |
| Sept 2018 | - | -$199.22 M(+58.9%) | -$625.30 M(+13.7%) |
| June 2018 | - | -$125.39 M(-29.1%) | -$550.13 M(+4.3%) |
| Mar 2018 | - | -$176.92 M(+42.9%) | -$527.43 M(+8.3%) |
| Dec 2017 | -$487.00 M(+30.8%) | -$123.77 M(-0.2%) | -$487.00 M(+5.5%) |
| Sept 2017 | - | -$124.04 M(+20.8%) | -$461.44 M(+6.5%) |
| June 2017 | - | -$102.70 M(-24.8%) | -$433.23 M(+4.8%) |
| Mar 2017 | - | -$136.48 M(+39.0%) | -$413.30 M(+11.0%) |
| Dec 2016 | -$372.26 M(+84.2%) | -$98.22 M(+2.5%) | -$372.26 M(+12.7%) |
| Sept 2016 | - | -$95.83 M(+15.8%) | -$330.20 M(+11.9%) |
| June 2016 | - | -$82.77 M(-13.3%) | -$295.21 M(+9.7%) |
| Mar 2016 | - | -$95.44 M(+69.9%) | -$269.16 M(+33.2%) |
| Dec 2015 | -$202.09 M(+15.7%) | -$56.16 M(-7.7%) | -$202.09 M(+8.6%) |
| Sept 2015 | - | -$60.84 M(+7.3%) | -$186.09 M(+10.0%) |
| June 2015 | - | -$56.72 M(+100.0%) | -$169.15 M(+5.1%) |
| Mar 2015 | - | -$28.36 M(-29.4%) | -$160.90 M(-7.8%) |
| Dec 2014 | -$174.60 M | -$40.16 M(-8.5%) | -$174.60 M(+10.7%) |
| Sept 2014 | - | -$43.90 M(-9.4%) | -$157.69 M(+15.6%) |
| June 2014 | - | -$48.48 M(+15.2%) | -$136.45 M(+21.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$42.06 M(+80.9%) | -$111.96 M(+54.1%) |
| Dec 2013 | -$72.66 M(-41.4%) | -$23.25 M(+2.6%) | -$72.66 M(-38.9%) |
| Sept 2013 | - | -$22.66 M(-5.5%) | -$119.01 M(+22.9%) |
| June 2013 | - | -$23.98 M(+765.7%) | -$96.87 M(+0.6%) |
| Mar 2013 | - | -$2.77 M(-96.0%) | -$96.25 M(-22.4%) |
| Dec 2012 | -$123.96 M(+40.3%) | -$69.60 M(>+9900.0%) | -$123.96 M(+54.9%) |
| Sept 2012 | - | -$517.00 K(-97.8%) | -$80.04 M(-26.4%) |
| June 2012 | - | -$23.36 M(-23.3%) | -$108.81 M(-3.3%) |
| Mar 2012 | - | -$30.48 M(+18.7%) | -$112.50 M(+27.3%) |
| Dec 2011 | -$88.36 M(-0.8%) | -$25.68 M(-12.3%) | -$88.36 M(+4.9%) |
| Sept 2011 | - | -$29.29 M(+8.3%) | -$84.20 M(+5.2%) |
| June 2011 | - | -$27.05 M(+327.2%) | -$80.02 M(+1.7%) |
| Mar 2011 | - | -$6.33 M(-70.6%) | -$78.71 M(-11.6%) |
| Dec 2010 | -$89.07 M(+15.5%) | -$21.53 M(-14.3%) | -$89.07 M(+4.0%) |
| Sept 2010 | - | -$25.11 M(-2.5%) | -$85.68 M(+4.6%) |
| June 2010 | - | -$25.74 M(+54.2%) | -$81.90 M(-12.1%) |
| Mar 2010 | - | -$16.70 M(-7.9%) | -$93.14 M(+20.8%) |
| Dec 2009 | -$77.09 M(-240.9%) | -$18.13 M(-15.0%) | -$77.09 M(+18.4%) |
| Sept 2009 | - | -$21.32 M(-42.3%) | -$65.09 M(+4.9%) |
| June 2009 | - | -$36.98 M(+5554.6%) | -$62.06 M(-194.5%) |
| Mar 2009 | - | -$654.00 K(-89.3%) | $65.68 M(+20.0%) |
| Dec 2008 | $54.73 M(-71.0%) | -$6.13 M(-66.5%) | $54.73 M(+13.6%) |
| Sept 2008 | - | -$18.29 M(-120.2%) | $48.19 M(-83.4%) |
| June 2008 | - | $90.75 M(-882.2%) | $290.08 M(+53.1%) |
| Mar 2008 | - | -$11.60 M(-8.4%) | $189.44 M(+0.4%) |
| Dec 2007 | $188.73 M(-737.3%) | -$12.67 M(-105.7%) | $188.73 M(-4.0%) |
| Sept 2007 | - | $223.60 M(-2361.8%) | $196.50 M(-738.3%) |
| June 2007 | - | -$9.89 M(-19.7%) | -$30.78 M(-3.0%) |
| Mar 2007 | - | -$12.31 M(+151.1%) | -$31.74 M(+7.2%) |
| Dec 2006 | -$29.62 M(+60.7%) | -$4.90 M(+33.3%) | -$29.62 M(+36.5%) |
| Sept 2006 | - | -$3.68 M(-66.1%) | -$21.70 M(-11.8%) |
| June 2006 | - | -$10.85 M(+6.5%) | -$24.60 M(+20.8%) |
| Mar 2006 | - | -$10.19 M(-437.8%) | -$20.37 M(+10.5%) |
| Dec 2005 | -$18.43 M(-35.5%) | $3.02 M(-145.8%) | -$18.43 M(-22.7%) |
| Sept 2005 | - | -$6.58 M(-0.5%) | -$23.85 M(+8.1%) |
| June 2005 | - | -$6.62 M(-19.7%) | -$22.06 M(-15.8%) |
| Mar 2005 | - | -$8.25 M(+242.9%) | -$26.19 M(-8.4%) |
| Dec 2004 | -$28.58 M(+79.2%) | -$2.40 M(-49.8%) | -$28.58 M(+9.2%) |
| Sept 2004 | - | -$4.79 M(-55.4%) | -$26.17 M(+22.4%) |
| June 2004 | - | -$10.75 M(+1.1%) | -$21.38 M(+101.1%) |
| Mar 2004 | - | -$10.63 M | -$10.63 M |
| Dec 2003 | -$15.95 M(+766.7%) | - | - |
| Dec 2002 | -$1.84 M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly FCF year-on-year change?
- What is Alnylam Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM FCF year-on-year change?
What is Alnylam Pharmaceuticals annual free cash flow?
The current annual FCF of ALNY is $41.95 M
What is the all time high annual FCF for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual free cash flow is $188.73 M
What is Alnylam Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of ALNY is $39.52 M
What is the all time high quarterly FCF for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly free cash flow is $342.32 M
What is Alnylam Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, ALNY quarterly free cash flow has changed by +$84.62 M (+187.61%)
What is Alnylam Pharmaceuticals TTM free cash flow?
The current TTM FCF of ALNY is $16.06 M
What is the all time high TTM FCF for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM free cash flow is $318.87 M
What is Alnylam Pharmaceuticals TTM FCF year-on-year change?
Over the past year, ALNY TTM free cash flow has changed by -$25.88 M (-61.70%)